Compare Bristol-Myers Squibb Co (BMY) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Rigetti Computing Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.61 (market cap $116.30B), while Rigetti Computing Inc trades at $15.28 (market cap $5.35B). The key difference: Bristol-Myers Squibb Co is far larger — about 21.7× Rigetti Computing Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals.
| BMY | RGTI | |
|---|---|---|
Market Cap | $116.30B | $5.35B |
Sector | Health | Technology |
52-Week High | $62.37 | $56.34 |
52-Week Low | $42.60 | $12.72 |
Enterprise Value | $152.24B | $4.94B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Rigetti Computing (RGTI) trades at $15.36, down 7.13% in the last 24 hours, with a bearish technical signal but bullish oscillators. The company reported a net loss of $216.21 million in 2025, with a negative net income margin of -2,253.59%, while revenue grew to $7.09 million. Recent news highlights quantum computing interest following Quantinuum's IPO and Rigetti's infrastructure developments, including the Fab-1 facility and a 108-qubit contract.
Despite significant losses and cash burn, analyst consensus is strongly bullish with an 85.71% buy rating and a $32.67 price target, suggesting over 112% upside. Key risks include high cash burn rates, intense competition, and the long timeline to quantum advantage, requiring careful risk assessment for speculative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
